Delix Therapeutics has raised $100.0M in Series C funding to keep developing non-hallucinogenic versions of psychedelic compounds as treatments for mental health conditions.
The Boston-based company's discovery platform has produced a class of compounds it calls psychoplastogens, which it says carry favorable safety and therapeutic profiles without the hallucinatory effects of classic psychedelics. Delix is pushing those compounds through preclinical and clinical development with the goal of winning FDA approval for take-home medicines. The Series C drew a long list of backers, including Johnson & Johnson Innovation JJDC Inc, SV Health Investors' Dementia Discovery Fund, OMX Ventures, RA Capital Management, Artis Ventures, UC Investments Inc, Dolby Family Ventures, Bail Capital, PsyMed Ventures, Adage Capital Management, Hamilton Square Healthcare Partners, LP, Vestal Point Capital and YK Bioventures.
